Daily Stock Analysis, BPMP, Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts., priceseries

Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.. Daily Stock Analysis
Stock Information
Open
16.01
Close
16.08
High
16.18
Low
15.82
Previous Close
15.93
Daily Price Gain
0.15
YTD High
16.98
YTD High Date
Feb 20, 2019
YTD Low
13.80
YTD Low Date
May 7, 2019
YTD Price Change
0.68
YTD Gain
4.44%
52 Week High
20.88
52 Week High Date
Jul 24, 2018
52 Week Low
13.71
52 Week Low Date
Dec 28, 2018
52 Week Price Change
-3.49
52 Week Gain
-17.84%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 26. 2018
16.92
May 24. 2018
19.29
20 Trading Days
13.95%
Link
LONG
Dec 31. 2018
14.94
Jan 14. 2019
15.86
9 Trading Days
6.17%
Link
Company Information
Stock Symbol
BPMP
Exchange
NASDAQ
Company URL
http://www.blueprintmedicines.com
Company Phone
617-374-7580
CEO
Jeffrey W. Albers
Headquarters
Massachusetts
Business Address
38 SIDNEY STREET, SUITE 200, CAMBRIDGE, MA 02139
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001597264
About

Blueprint Medicines Corp. is a biopharmaceutical company, which engages in developing of kinase inhibitors for genomically defined subsets of cancer patients. It has developed a platform that combines genomics with a novel library of kinase inhibitors, enabling the development of potent highly selective compounds against clear genomic driver targets. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker and Alexis Borisy in October 2008 and is headquartered in Cambridge, MA.

Description

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. Its lead drug candidates include BLU-285, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V, abnormally active receptor tyrosine kinases for patients with systemic mastocytosis, a disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor; and BLU-554, which is in Phase I clinical trials an orally available, potent, selective, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies, as well as candidates as inhibitors of neurotrophic tyrosine receptor kinase (NTRK) and predicted NTRK resistant mutants. In addition, the company is developing treatments that target cancer and rare genetic diseases. The company has agreements with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.